European Thyroid Journal · 2019 · 26 citations · 22 references
MedicineEndocrinologyPharmacotherapyDiabetologyEndocrine PharmacotherapyHormone BiochemistryDiabetes MellitusDiabetes PharmacotherapyGlucagon-like Peptide-1 Receptor AgonistsThyroid Axis RegulationThyroid DisordersThyroid EndocrinologySerum Thyroid-stimulating Hormone MeasurementThyroid Function EvaluationThyroid Function TestsThyroid Stimulating Hormone PhysiologyThyroid Volume AssessmentThyroid Volume EstimationThyroid-stimulating Hormone StimulationThyroid-stimulating Hormone Testing
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) analogues are now widely used for the treatment of type 2 diabetes mellitus (DM). Many binding sites for GLP-1 have been demonstrated in the specific tissue compartments of organs in-cluding the brain and thyroid. The aim of this study was to investigate the effect of exenatide treatment on thyroid-stimulating hormone (TSH) and thyroid volume in diabetic patients without thyroid disease. MATERIAL AND METHODS: The study included 46 diabetic patients without thyroid disease who were receiving exenatide treatment. Comparisons were made of total thyroid volume and serum concentrations of TSH at baseline and after 6 months of follow-up. RESULTS: > 0.05). CONCLUSIONS: Exenatide treatment for 6 months significantly decreased serum TSH concentration but did not affect thyroid volume in diabetic patients without thyroid disease.
22
Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
Michael Elashoff, Aleksey V. Matveyenko, Belinda Gier et al. · Gastroenterology · 2011 · 931 citations · Full text
Medicine, Endocrinology, Oncology +14